Hypohidrotic ectodermal dysplasia

Meet the patient — temperature elevation plus delayed teeth

A young child has sparse fine hair, conical teeth and recurrent temperature elevation in hot weather. You should protect the child from overheating while you evaluate infection separately; neither the facial appearance nor a single feature proves HED.[2][5]

Definition and classification — HED is a phenotype, not one gene

The exam triad is hypohidrosis or anhidrosis + hypotrichosis + hypodontia. Expression is variable: a person need not have complete absence of sweat, hair or teeth, and mildly affected relatives may be recognised only after a molecular diagnosis in the family.[1][6]

Epidemiology and phenotype variability

Do not quote a universal birth incidence. A Danish population study estimated molecularly confirmed XLHED prevalence at 1.6 per 100,000, while broader algorithmic case-finding produced a much higher possible-HED estimate; ascertainment and case definition therefore matter.[14]

Heterozygous females are not simply “unaffected carriers.” Random X-chromosome inactivation produces patchy or variable sweating, hair and dental findings; a systematic review found manifestations were frequent but heterogeneous, so history and examination remain important.[6][13]

Pathophysiology — build the appendage, then explain the triad

The canonical developmental signal is EDA-A1 ligand → EDAR receptor → EDARADD adaptor → canonical NF-κB activation. It operates during fetal appendage development; impaired signalling disrupts induction and patterning of eccrine sweat glands, hair follicles and teeth.[3][4]

Pathogenic variants can reduce ligand production, processing, receptor binding or downstream signalling; “complete loss of function at every step” is too absolute. WNT10A-associated HED belongs in the genetic differential but is not the EDAR adaptor.[2][4]

Clinical presentation — look beyond the triad

Heat and skin

Reduced or absent sweating causes heat intolerance and recurrent non-infectious temperature elevation, especially in infancy, hot weather, febrile illness or exercise. Xerosis and eczema are common, but the degree of hypohidrosis varies.[5][6][15]

Hair and nails

Scalp hair is often sparse, fine and lightly pigmented; eyebrows, eyelashes and body hair may also be reduced. Trichoscopy can document reduced density and shaft abnormalities, but it is supportive rather than diagnostic. Nail change in HED is variable; marked nail dystrophy with preserved sweating should redirect you toward Clouston syndrome.[7][11]

Teeth, face and growth

Hypodontia or oligodontia, conical crowns and delayed eruption produce feeding, speech, occlusal and psychosocial consequences. A recognisable facial gestalt may occur, but severity varies and facial appearance alone must not be used as a diagnostic test.[2][6][8]

Mucosal, ENT, eye and respiratory features

Hypoplastic mucous glands can cause nasal dryness and concretions, thick respiratory secretions, recurrent sinus or respiratory symptoms, dry eye and reduced salivary flow. These symptoms can occur in classic XLHED without primary immunodeficiency; severe, invasive, opportunistic or otherwise unusual infection should trigger immunology review for EDA-ID or another immune disorder.[2][5][12]

Differential diagnosis — one feature is never enough

Clinical assessment and diagnosis

What to ask and examine

Map heat tolerance, unexplained temperature episodes, eruption and shape of teeth, hair and nail changes, eczema, ENT/eye/respiratory symptoms, feeding and speech. Draw a three-generation pedigree, but do not assign inheritance from phenotype alone.[2][5]

Molecular confirmation

After clinical recognition, offer genetics review and phenotype-directed molecular testing. A panel should include EDA, EDAR, EDARADD and WNT10A at minimum, with broader ectodermal-dysplasia genes when the phenotype warrants it. Cascade testing follows identification of a familial pathogenic variant; a nondiagnostic result does not erase a convincing phenotype.[2]

Sweat, dental and biopsy assessment

Sweat testing is supportive, not mandatory. Iodine–starch mapping can demonstrate patchy sweating in heterozygous females; specialised pilocarpine-induced sweat volume or pore assessment may quantify function. Arrange paediatric dental assessment by about age one or at diagnosis, with age- and indication-appropriate imaging rather than a mandatory early panoramic radiograph. Skin biopsy is not routine when phenotype and genetics are diagnostic.[2][13]

[2]

Emergency heat-risk care — cool first, investigate in parallel

There is no evidence-based universal ambient-temperature cutoff. Risk depends on heat, humidity, radiant exposure, exertion, clothing, illness, hydration, age and individual sweating capacity. Evaluate infectious fever separately; antipyretics do not replace physical cooling for environmental or exertional hyperthermia.[2][17]

Long-term management — cool, teeth, mucosa, support

Daily heat plan

Ensure reliable access to water and a cool environment; use shade, ventilation, misting, cooling garments or air conditioning as individually useful. Modify activity for conditions and symptoms, and provide a written nursery, school, sport and workplace plan with emergency contacts.[2]

Dental and craniofacial care

Refer early to a paediatric dental or craniofacial team. Removable partial or complete overdentures are commonly used through childhood and must be adjusted or replaced with growth. Implant timing and bone augmentation are individual MDT decisions; the systematic-review evidence is mainly case reports and case series, so “all implants wait until skeletal maturity” is too rigid.[8]

Add preventive dentistry, oral hygiene and fluoride planning, nutrition and speech assessment, orthodontic review and psychosocial support. The aim is function and participation, not merely cosmetic normalisation.[2][8]

Skin, hair, ENT, eye and respiratory care

Use regular fragrance-free emollients and gentle cleansing; treat dermatitis or secondary infection when present. Offer hair prostheses or cosmetic support if wanted, never as an obligation.[2][7]

Humidification and saline nasal care may reduce dryness and concretions; ENT can remove obstructive concretions and assess recurrent otitis, sinus disease or hearing symptoms. Use lubricating eye drops when indicated and seek ophthalmic review for persistent pain, redness, photophobia or visual change. Assess chronic cough, wheeze, sleep symptoms or recurrent infection and involve primary care, allergy/pulmonology or sleep services according to the phenotype.[2][5]

Genetic counselling — say the recurrence risk by inheritance

• Carrier female with an EDA variant: each pregnancy has a 50% chance of inheriting the variant; an affected son and a heterozygous daughter have different and variable phenotypes.
• Affected male with an EDA variant: all daughters inherit the variant; no sons inherit it from him.
• Autosomal recessive HED: when both parents are heterozygous, recurrence risk is 25% per pregnancy.
• Autosomal dominant HED: an affected heterozygous parent has a 50% transmission risk per pregnancy.
• Once the familial pathogenic variant is known, prenatal molecular diagnosis and preimplantation genetic testing may be discussed non-directively.[2]

Specialist programmes have used reduced fetal tooth-germ counts on mid-gestation ultrasound to help identify affected male fetuses, but this is not a universal substitute for molecular diagnosis. A 2025 report describes its use in trial screening and carrier decision-making, not a general-population screening standard.[16]

Investigational ectodysplasin A1 replacement — timing and limits matter

PMID 32250462 reports two separate intravenous trials. Phase I enrolled six adults with XLHED (four male, two female) for safety, pharmacokinetics and immunogenicity. The open-label phase II enrolled ten affected newborn infants with XLHED (nine male, one female) and also assessed pharmacodynamics/efficacy; postnatal treatment did not improve perspiration, thermoregulation, primary dentition, general development or sweat-gland outcomes. A later long-term report followed nine treated males: three of those postnatally treated neonates and six treated intra-amniotically from gestational week 26, who later had pilocarpine-inducible sweating and more permanent teeth than affected relatives. These non-randomised small groups and genotype/family comparisons, with disclosed commercial/patent relationships, cannot establish broad safety or efficacy.[9][15]

ER004 is investigational and is not routine standard care. As last verified by ClinicalTrials.gov in April 2025, EDELIFE (NCT04980638) was a recruiting, open-label, non-randomised, genotype-matched controlled phase 2 study with estimated enrolment 20 and no posted results. Its protocol uses three intra-amniotic doses of 100 mg/kg estimated fetal weight, about three weeks apart from gestational week 26; estimated primary completion is February 2027 and study completion December 2032.[10][16]

[9] [10] [16]

Complications, follow-up and prognosis

Preventable heat illness is the immediate threat. Long-term burdens include dental and craniofacial dysfunction, feeding or speech difficulty, xerosis/eczema, nasal and airway dryness, eye symptoms, recurrent respiratory morbidity and psychosocial distress. Severe infection changes the diagnosis pathway toward immune evaluation.[2][5][12]

Growth and psychomotor development are usually normal, but do not promise a universal “normal lifespan”: registry data include family histories of infant or childhood death, and older estimates are vulnerable to ascertainment bias. Follow-up should be individualised around heat safety, growth, dental development, hearing/ENT, eye and respiratory symptoms, school participation and transition to adult dental and genetics services.[2][5]

Exam application bank

Stem 1 — the hot child

A child with known HED becomes confused during sport. State the first actions: stop exertion, move to a cool area, remove excess clothing, begin active external cooling, call emergency services and give oral fluid only if alert and swallowing safely. Infection assessment follows in parallel when clinically indicated.[2][15]

Stem 2 — inheritance is not one line

For an affected boy with an EDA variant, examine the mother without calling her “unaffected,” offer variant-specific testing and counsel X-linked transmission. If testing instead identifies EDAR, EDARADD or WNT10A, re-derive the risk from the actual autosomal mode.[2][6]

Stem 3 — treatment evidence

Say: “Prenatal intra-amniotic ER004 is under phase 2 investigation; the study is open-label and non-randomised with no posted results, while published human experience remains small. It is not routine care.”[9][10][16]

Exam pearls and key takeaways

[2] [11] [12] [2] [8] [9] [14]

References

1. [1]Reyes-Reali J, Mendoza-Ramos MI, Garrido-Guerrero E, et al. Hypohidrotic ectodermal dysplasia: clinical and molecular review. International Journal of Dermatology, 2018.PMID 29855039
2. [2]Wright JT, Grange DK, Fete M Hypohidrotic Ectodermal Dysplasia. GeneReviews, 1993.PMID 20301291
3. [3]Mikkola ML. Molecular aspects of hypohidrotic ectodermal dysplasia. American Journal of Medical Genetics Part A, 2009.PMID 19681132
4. [4]Trzeciak WH, Koczorowski R. Molecular basis of hypohidrotic ectodermal dysplasia: an update. Journal of Applied Genetics, 2016.PMID 26294279
5. [5]Fete M, Hermann J, Behrens J, et al. X-linked hypohidrotic ectodermal dysplasia (XLHED): clinical and diagnostic insights from an international patient registry. American Journal of Medical Genetics Part A, 2014.PMID 24664614
6. [6]Anbouba GM, Carmany EP, Natoli JL. The characterization of hypodontia, hypohidrosis, and hypotrichosis associated with X-linked hypohidrotic ectodermal dysplasia: A systematic review. American Journal of Medical Genetics Part A, 2020.PMID 31981414
7. [7]Peña-Romero AG, Sáez-de-Ocariz M, Toussaint-Caire S, et al. Clinical, trichoscopy, and light microscopic findings in hypohidrotic ectodermal dysplasia: Report of 21 patients and a review of the literature. Pediatric Dermatology, 2021.PMID 33085121
8. [8]Schnabl D, Grunert I, Schmuth M, et al. Prosthetic rehabilitation of patients with hypohidrotic ectodermal dysplasia: A systematic review. Journal of Oral Rehabilitation, 2018.PMID 29679503
9. [9]Schneider H, Schweikl C, Faschingbauer F, et al. A Causal Treatment for X-Linked Hypohidrotic Ectodermal Dysplasia: Long-Term Results of Short-Term Perinatal Ectodysplasin A1 Replacement. International Journal of Molecular Sciences, 2023.PMID 37108325
10. [10]Schneider H, Hadj-Rabia S, Faschingbauer F, et al. Protocol for the Phase 2 EDELIFE Trial Investigating the Efficacy and Safety of Intra-Amniotic ER004 Administration to Male Subjects with X-Linked Hypohidrotic Ectodermal Dysplasia. Genes, 2023.PMID 36672894
11. [11]Mellerio J, Greenblatt D Hidrotic Ectodermal Dysplasia 2. GeneReviews, 1993.PMID 20301379
12. [12]Döffinger R, Smahi A, Bessia C, et al. X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling. Nature Genetics, 2001.PMID 11242109
13. [13]Clarke A, Burn J. Sweat testing to identify female carriers of X linked hypohidrotic ectodermal dysplasia. Journal of Medical Genetics, 1991.PMID 1865470
14. [14]Nguyen-Nielsen M, Skovbo S, Svaneby D, et al. The prevalence of X-linked hypohidrotic ectodermal dysplasia (XLHED) in Denmark, 1995-2010. European Journal of Medical Genetics, 2013.PMID 23416623
15. [15]Körber I, Klein OD, Morhart P, et al. Safety and immunogenicity of Fc-EDA, a recombinant ectodysplasin A1 replacement protein, in human subjects. British Journal of Clinical Pharmacology, 2020.PMID 32250462
16. [16]Schneider H, Schneider M, Lia M, et al. Attitudes of female carriers of X-linked hypohidrotic ectodermal dysplasia towards prenatal treatment and their decisions during a pregnancy with a male fetus. Orphanet Journal of Rare Diseases, 2025.PMID 40234959
17. [17]Eifling KP, Gaudio FG, Dumke C, et al. Wilderness Medical Society Clinical Practice Guidelines for the Prevention and Treatment of Heat Illness: 2024 Update. Wilderness & Environmental Medicine, 2024.PMID 38425235
18. [18]Bohring A, Stamm T, Spaich C, et al. WNT10A mutations are a frequent cause of a broad spectrum of ectodermal dysplasias with sex-biased manifestation pattern in heterozygotes. American Journal of Human Genetics, 2009.PMID 19559398